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A simple, specific, precise, accurate, linear, rapid, economic and validated stability indicating an RP-HPLC 
method for the simultaneous quantification of cefepime and tazobactam in a dry injection dosage form 
has been developed. Separation was performed on a 5 µm ACE C18 column with phosphate buffer, pH 
adjusted to 4.5 with phosphoric acid: methanol (70:30) at a flow rate of 1 mL/min and at a temperature 
of 25 °C. Regression analysis showed linearity at a detector wavelength of 290 nm in the range of 200-
600 μg/mL for cefepime and 25-75 μg/mL for tazobactam. All of the analytes were adequately resolved 
with acceptable tailing. The percentage content found for cefepime was 99.98% and of tazobactam 
was 99.49% in the parenteral formulation. The method was validated in terms of linearity, precision, 
accuracy, specificity, robustness and system suitability according to ICH guidelines. Stress degradation 
studies were performed on the placebo and drug products, drugs of interest were well resolved from the 
degradation products. The developed method was effectively applied for the simultaneous quantification 
of cefepime and tazobactam in a dry injection formulation.
Uniterms: High performance liquid chromatography/quantitative analysis. Cefepime/quantificação. 
Tazobactam/quantificação. Dry injection formulation/quantitative analysis. Pharmaceutical formulations/
degradation studies. 
Desenvolveu-se método específico, preciso, exato, linear, rápido e econômico, de validação de 
estabilidade, indicando o método de CLAE-FR para a quantificação simultânea de cefepima e tazobactam 
na forma de dosagem injetável seca. A separação foi realizada em coluna C18 de ACE 5 mM com 
tampão fosfato, pH ajustado para 4,5 com ácido fosfórico:metanol (70:30), em fluxo de 1 mL/min e 
temperatura de 25 °C. A análise de regressão mostrou linearidade no detector de comprimento de onda de 
290 nm, na faixa de 200-600 μg/mL, para cefepima, e 25-75 μg/mL, para tazobactam. Todos os analitos 
foram, adequadamente, resolvidos com cauda aceitável. O teor percentual encontrado na formulação 
parenteral foi de 99,98%, para cefepima, e de 99,49%, para o tazobactam. O método foi validado em 
termos de linearidade, precisão, exatidão, especificidade, robustez e adequação do sistema de acordo 
com as diretrizes ICH. Estudos de degradação por estresse foram realizados no grupo placebo e nos 
medicamentos e os fármacos de interesse foram bem resolvidos a partir dos produtos de degradação. O 
método desenvolvido foi efetivamente aplicado para quantificação simultânea de cefepima e tazobactam 
na formulação injetável seca.
Uniterms: CLAE-FR. Cromatografia líquida de alta eficiência/fase reversa/análise quantitativa. Cefepima/
quantificação. Tazobactam/quantificação. Formulação injetável seca/análise quantitativa. Formulações 
farmacêuticas/estudo de degradação.
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INTRODUCTION
ICH and WHO recommend that analysis of 
pharmaceutical finished products during stability testing 
should be conducted using a validated stability-indicating 
method. In this study, ICH and WHO recommendations 
were therefore kept in mind for the simultaneous 
estimation of cefepime (CEF) and tazobactam (TAZ).
CEF is a fourth-generation, semi-synthetic, broad 
spectrum, cephalosporin. Chemically, it is 1-[[(6R,7R)-
7-[2-(2-amino-4-thiazolyl)-glyoxylamido]-2-carboxy-8-
oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-
methylpyrrolidinium chloride, 72-(Z)-(O-methyloxime), 
monohydrochloride, monohydrate (Figure 1). It is used 
in the treatment of moderate-to-severe infections, such as 
pneumonia, uncomplicated urinary tract infections, skin 
and soft tissue infections, intra-abdominal infections and 
febrile neutropenia.
TAZ is semi-synthetic parenteral penicillin. It is a 
β-lactamase inhibitor with a broad spectrum of antibacterial 
activity against most gram positive, gram negative aerobic 
and anaerobic bacteria (Ghafur, Ashwini, Priyadarshini, 
2012.). Chemically, it is known as (2S,3S,5R)-3-methyl-7-
oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo 
[3.2.0] heptane-2-carboxylic acid 4, 4-dioxide (Figure 2).
An extensive literature search was carried out on 
analytical methods that were developed to estimate the 
combination of CEF and TAZ. The literature survey 
revealed that several spectrophotometric methods had been 
reported for the determination of CEF alone as well as for 
stability and degradation studies (Singh, 2013; Moreno, 
Salgado, 2012; Chahana, Harsha, Chhaganbhai, 2013). 
CEF in combination with other drugs can be estimated 
using numerous liquid chromatography methods (Palacios 
et al., 2005; Nanda et al., 2012; Pedroso, Salgado, 2014). 
TAZ was also successfully determined by HPLC methods.
However, there is no RP-HPLC method available 
for stability indicating the validated simultaneous 
quantification of CEF and TAZ in combination so far. 
Hence, this research work was carried out with the 
objective of developing a simple RP-HPLC method for 
the simultaneous quantification of CEF and TAZ in bulk 
as well as in a dry injection formulation and its application 
to stress degradation studies.
MATERIAL AND METHODS
Instruments
The HPLC system consisted of a Waters E2695 
with EMPOWER software, a POLMAN pH meter, model 
FIGURE 1- Chemical structure of CEF.
FIGURE 2 - Chemical structure of TAZ.
LP139SA, and a Sartorius analytical Balance, model 
BSA224S-CW.
Chemical reagents
Methanol was of HPLC grade, while all other 
chemicals and reagents, including orthophosphoric acid, 
potassium dihydrogen phosphate, and hydrochloric acid, 
were of analytical reagent grade and were supplied by 
Merck. Double-distilled water and milli-Q water was 
used for all of the experiments, as appropriate. Filtration 
of the mobile phase was performed using 0.45 mm nylon 
filters (Millipore, USA). CEF and TAZ drug samples 
were gifted by Aurobindo Pharma Pvt. Ltd. (Hyderabad, 
India).
Preparation of standard solutions
Standard stock solutions of the two drugs were 
prepared by accurately weighing 40 mg CEF and 5 mg 
TAZ and then dissolving this in a few mL of methanol. 
The volume of this solution was then made up to 100 mL 
with the mobile phase. The stock solution was diluted 
with mobile phase to obtain final concentrations equal 
to 400 μg/mL CEF and 5 μg/mL TAZ. The solution was 
filtered using a nylon filter before analysis.
Preparation of sample solution
The dry injection formulation containing 1000 mg 
of CEF and 125 mg of TAZ was reconstituted with 
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sterile water to a volume of 10 mL. From this, 2 mL was 
transferred into a 100 mL volumetric flask and diluted up 
to the mark with mobile phase to obtain a concentration 
equal to 2000 μg/mL of CEF and 250 μg/mL of TAZ. The 
above solution was further diluted with mobile phase to 
obtain final concentrations within the linearity range to 
quantify them using the proposed RP-HPLC method.
Method validation
The proposed method was validated as per ICH 
guidelines for the following parameters: linearity and 
range, precision, accuracy, specificity, ruggedness, 
robustness, limit of detection (LOD), limit of quantitation 
(LOQ), system suitability and forced degradation studies.
Linearity
Appropriate aliquots of standard stock solution 
were diluted with diluent to obtain final concentrations 
of CEF and TAZ in the range of 200-600 μg/mL and 
25-75 μg/mL, respectively. A 10 μL aliquot of each sample 
was injected six times for each concentration level and a 
calibration curve was constructed by plotting the average 
peak area versus the drug concentration.
Precision
Precision was checked for both the system and the 
developed method. The system precision was checked 
using standard CEF and TAZ solutions. The retention 
time and area of ten determinations were measured and 
the RSD (Relative Standard Deviation) was calculated. A 
homogenous sample of a single batch was analysed six 
times to determine the precision of the developed method. 
Percentage assay values and the RSD of the assay were 
calculated.
Accuracy
The accuracy of an analytical method is the 
closeness of test results obtained by that method to 
the true value. Accuracy of the proposed method was 
ascertained on the basis of a recovery study performed 
using the standard addition method. Accuracy was 
performed at three different levels for CEF and TAZ. A 
known quantity of CEF and TAZ standard was spiked at 
50%, 100% and 150% levels into the placebo. Analyses 
of samples were performed in triplicate for each level. 
The percentage recovery was calculated from the 
obtained results.
Specificity
The analytes should show no interference from 
other extraneous components and should be well resolved 
from them. Specificity is the procedure used to detect the 
analytes quantitatively in the presence of a component 
that may be expected to be present in the sample matrix.
Robustness
As defined by the ICH, the robustness of an analytical 
procedure refers to its capability to remain unaffected by 
small and deliberate variations in method parameters. 
The robustness was studied by evaluating the effect of 
small but deliberate variations in the chromatographic 
conditions. Different parameters that were altered to 
evaluate robustness of the method included flow rate by 
±0.2 mL/min, temperature by ± 5 °C and mobile phase 
composition.
Forced degradation studies
To determine whether the analytical method was 
able to indicate stability, a CEF and TAZ formulation 
was stressed under various conditions to conduct forced 
degradation studies. Intentional degradation was attempted 
in stress conditions of acidic (0.1 N HCl), basic (0.1 N 
NaOH), neutral (water), oxidative degradation (1% H2O2)
 
and thermal treatment (heated at 80 °C to evaluate the 
ability of the proposed method to separate CEF and TAZ 
from its degradation products). The test preparation was 
subjected to acid stress degradation by treating 5 mL of 
sample with 5 mL of 0.1 N HCL. The contents were mixed 
well and constantly stirred for 30 min and then neutralised 
with 5 mL of 0.1 N NaOH. Then, it was diluted as per 
the test procedure and injected into the HPLC system. 
Similarly, alkali (NaOH), peroxide degradation (H2O2), 
neutral degradation (60 °C for 60 min) and thermal 
degradation (80 °C for 30 min) tests were carried out.
RESULTS AND DISCUSSION
For the method development, several trials were 
carried out and the final optimised chromatographic 
conditions for the separation and quantification of CEF 
and TAZ in the bulk and dry injection formulation were 
reported. Preliminary studies involved using an ACE 
C18 column, with a 5 µm size of the packing material, 
and several mobile phase compositions for the effective 
separation of these two drugs. Using the ACE C18 Column, 
5 µm size, eluted with phosphate buffer of pH 4.5:MeOH 
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(70:30) by isocratic elution at a flow rate of 1 mL/min and 
a detection wavelength of 290nm with injection volume 
of 10 µL at 25 °C afforded the best separation of these 
analytes. The chromatogram of the optimised method is 
shown in Figure 3. The system suitability parameters are 
shown in Table I.
From the results of the assay study, the content of 
CEF was found to be 999 mg/mL (label claim percentage 
was 99.98%) while TAZ was 124.5 mg/mL (label claim 
percentage was 99.49%) (Table II).
Linearity
Linear calibration plots for the proposed method 
were obtained in concentration ranges of 200-600 μg/mL 
for CEF and 25-75 μg/mL TAZ. The linear regression 
equation for CEF was y=15625x-5844, with a correlation 
coefficient of 0.999 (Figure 4), and for TAZ it was 
y=82449x-9735, with a correlation coefficient of 0.999 
(Figure 5).
Accuracy
The accuracy of the method was determined by the 
standard addition method. Three levels of solutions (50, 
100 and 150%) of the nominal analytical concentrations 
were prepared. Percentage recoveries along with standard 
deviations and relative standard deviations for each 
analyte (n=6) are given in Table III. Recovery studies 
showed the method to be highly accurate and suitable for 
the intended use.
FIGURE 3 - Chromatogram obtained after optimisation.
TABLE I - Results of system suitability parameters
Sample
Retention 
time Area
USP 
resolution
USP 
Tailing
Plate 
count
CEF 1.477 6286610 1.480 3671
TAZ 2.616 4169897 7.225 1.442 4969
TABLE II - Assay of CEF and TAZ in formulation
Formulation
CEF TAZ
Label claim 
(mg)
Amount 
found (mg) 
A.M± SD
%Assay % RSD
Label claim 
(mg)
Amount 
found(mg) 
A.M± SD
%Assay %RSD
XEPIME 
TAZ
1000 999.66±0.152 99.98 0.0152 125 124.5±0.458 99.49 0.367
FIGURE 4 - Linearity plot of CEF.
FIGURE 5 - Linearity plot of TAZ.
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TABLE III - Accuracy of the proposed HPLC method
Amount of 
test solution
Recovery 
level (%)
Recovery of 
analyte
Amount of 
std added
Theoretical 
content 
(µg/mL)
Amount 
found(µg/mL) 
A.M± SD (n=3)
Recovery (%) % RSD
40
0 
µ
g/
m
L
 C
E
F
 
50
 µ
g/
m
L
 T
A
Z
0
CEF 0 400 398.47±1.917 99.61 0.481
TAZ 0 50 49.59 ±0.002 99.18 0.041
50
CEF 200 600 599.95±0.630 99.91 0.105
TAZ 25 75 74.67±0.110 99.99 0.147
100
CEF 400 800 798.64±0.076 99.92 0.001
TAZ 50 100 99.63±0.574 99.63 0.576
150
CEF 600 1000 998.43 ±0.165 99.48 0.016
TAZ 75 125  124.46±0.450 99.57 0.362
Precision
The system and the developed method produced 
satisfactory precision results. The replicate estimation 
of a dry injection formulation analysed by the proposed 
method yielded quite consistent results, indicating the 
repeatability of the method. The study showed %R.S.D.<2 
for both CEF and TAZ (Table IV).
Limit of detection and limit of quantification
The Limit of detection (LOD) and Limit of 
Quantification (LOQ) were determined by making different 
solutions with decreasing concentrations of analytes. 
LOD was found to be 0.475 μg/mL and 0.148 μg/mL 
for CEF and TAZ, respectively (S/N ratio 3:1). LOQ was 
found to be 1.585 μg/mL and 0.494 μg/mL for CEF and 
TAZ, respectively (S/N ratio 10:1).
Robustness
Robustness of the method was performed by 
slightly varying the chromatographic conditions. The 
results showed a negligible effect on the chromatographic 
parameters by slight variations in chromatographic 
conditions with respect to mobile phase, temperature and 
flow rate. Results are presented in Table V.
Stress degradation studies
All of the stress conditions applied were capable 
of degrading both of the drugs. The degradation data are 
shown in Table VI; it was shown that CEF degradation was 
more efficient in acidic than other stress conditions and 
TAZ degradation was lower in all of the stress conditions. 
The drugs of interest peaks were well separated from the 
degradation product peaks and the resolution was found to 
be more than 2. Hence, the developed RP-HPLC method 
has the ability to quantify CEF and TAZ in the presence 
of degradation products.
CONCLUSION
There is currently no RP-HPLC method that is 
capable of the simultaneous estimation of CEF and TAZ 
in the injection dosage form. Also, no stress degradation 
studies have been performed for this combination. The 
developed method was simple, rapid, precise, accurate 
and economical, and can be employed for the routine 
estimation of CEF and TAZ in injection dosage. All of the 
validation parameters were found to be highly acceptable 
indicators for specificity, linearity and range, accuracy, 
precision, ruggedness, LOD, LOQ and robustness. The 
stress degradation studies of CEF and TAZ were checked 
by the proposed method and the degradation peaks were 
TABLE IV - Results of method precision of CEF and TAZ
Injection no.
CEF TAZ
Retention 
Time 
(min )
Peak 
Area
Retention 
Time 
(min )
Peak 
Area
1 1.480 6264001 2.638 4139862
2 1.480 6266419 2.637 4132529
3 1.481 6269715 2.638 4131457
4 1.479 6262821 2.637 4137014
5 1.481 6267552 2.640 4136180
6 1.480 6266298 2.640 4133972
Mean 6266134 4135169
SD 2468.5 3118.70
% RSD 0.039 0.075
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well separated from the sample peaks. The developed 
method was successfully applied for the simultaneous 
quantification of CEF and TAZ in a dry injection 
formulation.
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